Exton, Pennsylvania, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The biologic treatment armamentarium for plaque psoriasis has arguably experienced some of the most successful developments in recent autoimmune ...
Rani Therapeutics Holdings, Inc. targets a new potential oral delivery of biologic drugs via the RaniPill. This could eventually replace injections and improve patient adherence. Their pipeline has RT ...
TORONTO, April 8, 2025 /PRNewswire/ - AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced a new pipeline program in collaboration with a leading global ...
Hosted on MSN
Eli Lilly closes in on a deal to buy biotech Ventyx
Eli Lilly is moving to deepen its bet on inflammatory disease, striking a deal to acquire biotech player Ventyx Biosciences in a transaction that values the company in the low billions of dollars. The ...
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis PeptiDream Inc., a public Kanagawa, ...
Biologics are complex medications produced through biological processes or from living organisms such as proteins and genes. Biosimilars are what they sound like — similar to, but not the same as, an ...
Icotrokinra, a novel oral interleukin (IL)-23 inhibitor, provided a level of response in moderate-to-severe plaque psoriasis that is similar to that previously reported with injectable biologics, ...
Zacks Investment Research on MSN
BD and Ypsomed expand partnership to target growing biologics market
Becton, Dickinson and Company BDX, popularly known as BD, recently announced the expansion of its partnership with Ypsomed to ...
Management believes VIVI Med strengthens TempraMed's long-term growth profile by increasing product breadth, reducing reliance on any single medication format, and supporting future reimbursement, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results